TNDM Stock Recent News
TNDM LATEST HEADLINES
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2024 results after the financial markets close on Wednesday, February 26, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2024 financial and operating results. A live webcast of the call.
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. The research collaboration will rely on the UVA Center for Diabetes Technology's groundbreaking work to improve care for patients w.
Flat revenue growth might be in store for the company in a very crucial market.
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
It earned a regulatory nod in one of the largest markets in the world. Approval was granted for a system to deliver an ultra-rapid insulin product developed by Eli Lilly.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). “High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Contr.
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.